Literature DB >> 29078648

Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.

Periklis Perikleous1, David A Waller1.   

Abstract

Parenchymal cancers of lung, breast, gastrointestinal tract and ovaries as well as lymphomas and mesotheliomas are among the most common cancer types causing malignant effusions, though almost all tumour types have been reported to cause a malignant effusion. The prognosis heavily depends on patients' response to systemic therapy however, regardless of the causing pathology and histopathologic form, malignant pleural disease is normally associated with a poor prognosis. To date, there are not sufficient data to allow accurate predictions of survival that would facilitate decision making for managing patients with malignant pleural diseases. Interventions are directed towards drainage of the effusion and, when appropriate, concurrent or subsequent pleurodesis or establishing long-term drainage to prevent re-accumulation. The rate of re-accumulation of the pleural effusion, the patient's prognosis, and the severity of the patient's symptoms should guide the subsequent choice of therapy. In contemporary medicine, not many cancers have managed to generate as intense debates concerning treatment, as malignant pleural mesothelioma. The relative advantages of surgery, radiation, chemotherapy and any combination of the three are continuously reassessed and reconsidered, even though not always based on scientific evidence. The aim of surgery in mesothelioma may be prolongation of life, in addition to palliation of symptoms. Longer recovery periods from more extensive surgical procedures could be justified, in carefully selected patients. Surgical options include: Video assisted thoracoscopic (VATS) pleurodesis, VATS partial pleurectomy (VATS PP)-both parietal and visceral; open pleurectomy decortication (PD)-with an extended option (EPD) and extrapleural pneumonectomy (EPP). Current evidence implies that EPD can be performed reliably in specialised centres with good results, both in terms of mortality and survival; however, no operation has yet been shown to be beneficial in a prospective randomized controlled clinical trial.

Entities:  

Keywords:  Thoracic surgery; asbestos; breast cancer; lymphoma; malignant; mesothelioma; mesothelioma and radical surgery (MARS); pleural diseases; thoracotomy; video assisted thoracoscopic (VATS)

Year:  2017        PMID: 29078648      PMCID: PMC5638168          DOI: 10.21037/jovs.2017.05.05

Source DB:  PubMed          Journal:  J Vis Surg        ISSN: 2221-2965


  102 in total

Review 1.  The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma.

Authors:  Anthony Linton; Janette Vardy; Stephen Clarke; Nico van Zandwijk
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-27       Impact factor: 6.312

Review 2.  Thoracoscopy: medical versus surgical-in the management of pleural diseases.

Authors:  Samira Shojaee; Hans J Lee
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

3.  Carcinomatous involvement of the pleura: an analysis of 96 patients.

Authors:  B Chernow; S A Sahn
Journal:  Am J Med       Date:  1977-11       Impact factor: 4.965

4.  Mesothelioma--VATS biopsy and lung mobilization improves diagnosis and palliation.

Authors:  M W Grossebner; A A Arifi; M Goddard; A J Ritchie
Journal:  Eur J Cardiothorac Surg       Date:  1999-12       Impact factor: 4.191

5.  Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography.

Authors:  Jacob S Toaff; Ur Metser; Maya Gottfried; Odelia Gur; Maher E Deeb; Gennady Lievshitz; Diego Mercer; Einat Even-Sapir
Journal:  Invest Radiol       Date:  2005-04       Impact factor: 6.016

6.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.

Authors:  Helen E Davies; Eleanor K Mishra; Brennan C Kahan; John M Wrightson; Andrew E Stanton; Anur Guhan; Christopher W H Davies; Jamal Grayez; Richard Harrison; Anjani Prasad; Nicola Crosthwaite; Y C Gary Lee; Robert J O Davies; Robert F Miller; Najib M Rahman
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

7.  Catheter tract metastasis associated with indwelling pleural catheters.

Authors:  Rajesh Thomas; Charley A Budgeon; Yi Jin Kuok; Catherine Read; Edward T H Fysh; Sean Bydder; Y C Gary Lee
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

8.  Management of chylothorax.

Authors:  N L Browse; D R Allen; N M Wilson
Journal:  Br J Surg       Date:  1997-12       Impact factor: 6.939

9.  Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.

Authors:  Bernard Duysinx; Delphine Nguyen; Renaud Louis; Didier Cataldo; Tarik Belhocine; Pierre Bartsch; Thierry Bury
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

10.  Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma.

Authors:  A Knuuttila; L Kivisaari; A Kivisaari; M Palomäki; P Tervahartiala; K Mattson
Journal:  Acta Radiol       Date:  2001-09       Impact factor: 1.701

View more
  2 in total

1.  Video-assisted thoracoscopic PlasmaJet ablation for malignant pleural mesothelioma.

Authors:  Periklis Perikleous; Nizar Asadi; Vladimir Anikin
Journal:  J Vis Surg       Date:  2018-03-20

Review 2.  Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.

Authors:  David Michael Abbott; Chandra Bortolotto; Silvia Benvenuti; Andrea Lancia; Andrea Riccardo Filippi; Giulia Maria Stella
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.